Objectives: Brentuximab vedotin is an orphan drug currently indicated for treatment of patients with refractory/relapsed hodgkin lymphoma CD30+ following prior Auto Stem Cell Transplant (ASCT) or following two prior chemotherapy regimens. This is a group of patients with a reported median survival of 12 months, with no defined standard of care and for whom clinical trials are single armed due to lack of appropriate comparators and scarcity of patients. Hence, an indirect comparison was performed to determine the cost-effectiveness of brentuximab vedotin in different countries. MethOds: A three state Markov model was developed. Effectiveness of brentuximab vedotin was obtained from the clinical trial of Gopal 2012. Effectiveness for the control group was obtained from 3 clinical trials evaluating survival of post-ASCT patients where data was disaggregated based on the patients´ response to prior ASCT/chemotherapy. The assumption was that only patients with ASCT/chemotherapy failure would serve as controls. The treatments received by the control group were based on the review of Martinez 2013, where 64% received chemotherapy, 29% AlloSCT and 8% AutoSCT. Simulations were run for the Mexican and Venezuelan contexts. Direct medical costs were obtained from the local public sectors and WHO-CHOICE. Results: For the base case scenario of both countries the ICERs (USD/LYG) were respectively $38,614.34 (Mex) and $57,854.07 (Ven), which compares favorably against accepted ICERs in the orphan drugs field. In the univariate sensitivity analysis the model was mainly sensitive to the costs of brentuximab, AutoSCT and AlloSCT. cOnclusiOns: Brentuximab vedotin is a cost-effective alternative for both countries, especially in the space of orphan drugs. The low costs of AutoSCT and AlloSCT in Venezuela relative to its GDP were what mainly accounted for higher ICERs. Differences in chemotherapy usage and costs did not alter the model. As a limitation, local epidemiology was not accounted for due to lack of data. Objectives: to perform cost-effectiveness analysis fulvestrant 500mg (F500) for the treatment of first progression or recurrence of advanced breast cancer in postmenopausal patients compared with anastrozole 1mg (ANAS1), letrozole 2.5mg (LET2,5), exemestane 25mg (EXE25) and exemestane 25mg+everolimus 10mg (EXE25+EVE10). MethOds: the data on efficacy and safety of 2-line hormonal therapy of breast cancer were derived from a network meta-analysis and clinical data publication for overall survival (OS), progression free survival (PFS) and serious adverse events (SAE). We considered the direct costs on second and third line hormonal therapy and resource utilization. Data on resource usage, were based on expert opinion and open sources. 1-way sensitivity analyses were conducted. Results: in terms of OS F500 (mean 23.33 month) was as effective as ANAS1 (22.12) and more effective than LET2.5 (17.44) and EXE25 (18.31). The highest incremental cost-effectiveness ratio (ICER) estimated for F500 versus ANAS1 was 84,592 USD per year with incremental effectiveness 1.21 month. The lowest ICER estimated for F500 versus LET2.5 was 22,873 USD per year with incremental effectiveness 5.90 month. The ICER for F500 versus EXE25 was 25,890 USD per year. In terms of PFS EXE25+EVE10 was more effective and costly, than F500. The CER for F500 was 1,714 USD per year versus 4,215 USD for EXE25+EVE10. A series of one-way sensitivity analyses showed this result is robust to variations in costs of drugs, physician examination, and variation in costs associated with SAE. cOnclusiOns: the use of F500 is more effective than LET2.5 and EXE25, and at least as efficacious as ANAS1 in terms of OS among postmenopausal women with advanced breast cancer after failure on 1-line endocrine therapy. In terms of PFS F500 less efficacious than EXE25+EVE10, however substantially cheaper. From perspective of federal health care system, the cost of LYG for F500 is less than the willingness to pay threshold.
Objectives: to perform cost-effectiveness analysis fulvestrant 500mg (F500) for the treatment of first progression or recurrence of advanced breast cancer in postmenopausal patients compared with anastrozole 1mg (ANAS1), letrozole 2.5mg (LET2,5), exemestane 25mg (EXE25) and exemestane 25mg+everolimus 10mg (EXE25+EVE10). MethOds: the data on efficacy and safety of 2-line hormonal therapy of breast cancer were derived from a network meta-analysis and clinical data publication for overall survival (OS), progression free survival (PFS) and serious adverse events (SAE). We considered the direct costs on second and third line hormonal therapy and resource utilization. Data on resource usage, were based on expert opinion and open sources. 1-way sensitivity analyses were conducted. Results: in terms of OS F500 (mean 23.33 month) was as effective as ANAS1 (22.12) and more effective than LET2.5 (17.44) and EXE25 (18.31). The highest incremental cost-effectiveness ratio (ICER) estimated for F500 versus ANAS1 was 84,592 USD per year with incremental effectiveness 1.21 month. The lowest ICER estimated for F500 versus LET2.5 was 22,873 USD per year with incremental effectiveness 5.90 month. The ICER for F500 versus EXE25 was 25,890 USD per year. In terms of PFS EXE25+EVE10 was more effective and costly, than F500. The CER for F500 was 1,714 USD per year versus 4,215 USD for EXE25+EVE10. A series of one-way sensitivity analyses showed this result is robust to variations in costs of drugs, physician examination, and variation in costs associated with SAE. cOnclusiOns: the use of F500 is more effective than LET2.5 and EXE25, and at least as efficacious as ANAS1 in terms of OS among postmenopausal women with advanced breast cancer after failure on 1-line endocrine therapy. In terms of PFS F500 less efficacious than EXE25+EVE10, however substantially cheaper. From perspective of federal health care system, the cost of LYG for F500 is less than the willingness to pay threshold. Objectives: Cancer accounts for around 1.3 million deaths and € 50 billion in health care expenditure in the European Union. Balancing increasing treatment costs and prevalence will be increasingly difficult for governments to manage. Advances in immunotherapies provide hope for a cancer cure; however its cost might be out of reach for governments under current health economic evaluation methods which will be the aim of this research. MethOds: The years of life lost (YLL) in the UK due to cancer were obtained from the Institute of Health Metrics and Evaluation (IHME) database and multiplied by the NICE cost effectiveness threshold of £20,000 per Quality Added life Year (QALY), this gave a first estimate of the potential cost of a cancer cure that would be within an acceptable cost effectiveness threshold. This cost was then modified to take into account the quality of life (QoL) of the general population, QALY discounting, cancer onset age, and other demographics. YLL due to disability in cancer were not included in the calculation. Results: It is estimated that 32.4% of the total YLL per year in the UK (5,615,310) are a consequence of cancer. The cost of saving these YYL at £20,000 per QALY was estimated to be around £12 billion for all cancers per year, meaning an extra £425 in taxes would have to be generated Objectives: Standard treatment for localized prostate cancer is radical prostatectomy (PE) or radiation therapy (RT) which frequently cause erectile dysfunction (ED) and incontinence (IC). As tumor progression often is slow, active surveillance (AS) has been proposed as an alternative treatment strategy. This study compares the cost-effectiveness of the three treatment strategies in a German context. MethOds: Based on claims data of a German sickness fund we analyzed men diagnosed with prostate cancer (ICD-10 code C61) in 2008. Life years gained and complication rates of ED and IC as well as costs of inpatient and outpatient treatment, pharmaceuticals, physical therapy, medical aids and copayments were tracked for 2.5 years after the initial treatment. An excess-cost analysis was applied. Strategies were compared in an age-matched and comorbidity-adjusted approach. Results: The baseline study sample included 25,376 individuals. Exclusion of metastases, other cancer diagnoses and treatment strategies resulted in 910 men with PE, 292 with RT and 124 with AS. After matching 107 men remained in the AS group and 214 each in the PE and RT groups with a mean age of 70 years. Risk of long-term ED (PE: 0.112, RT: 0.009, AS: 0.056) and IC (PE: 0.313, RT: 0.009, AS: 0.084) was highest in the PE group. Compared to RT and AS, PE was associated with more life years gained during the cause of the study. Due to high inpatient costs of the initial surgery PE had ca. € 11,000 higher total per capita costs than RT and AS. cOnclusiOns: The analysis indicates that PE is associated with better prognosis and higher overall costs compared to RT and AS. 2.5 years follow-up might, however, not be enough to detect prostate cancer-specific deaths. Objectives: It is estimated that almost all cervical cancers are associated with HPV infection. In most industrialised countries, cervical screening and vaccination with a bivalent or quadrivalent vaccine are recommended to prevent the disease. The current study aimed to critically review the results of CEAs that have assessed the trade-off between screening and vaccination. MethOds: A systematic literature review was conducted in order to explore the cost-effectiveness of HPV vaccination strategies with or without different screening strategies within the geographical context of Western Europe, North America and Australia. Modelling approach, disease considered, vaccination/screening settings and costs were compared. Results: A total of 1,188 citations were identified and 20 studies were included in the review. Heterogeneity was seen across studies in terms of modelling approach, disease and prevention strategies considered. Inclusion of more HPV-related diseases significantly improves cost-effectiveness. The strategies combining screening and vaccination were found to be cost-effective when compared to vaccination or screening alone. In terms of screening strategy, HPV DNA testing with cytological triage showed a trend to be the optimal strategy in vaccinated girls. However the gain in benefits reduced as the interval between screenings is reduced. Delaying the starting age of screening could be cost saving, with a limited increase in risk of cancer. An increasing vaccine valence seemed to counterbalance the detrimental effect of delayed/less frequent screening while the total costs of cervical disease prevention/treatment may be maintained or decreased. Lastly, vaccine price seemed to affect the incremental cost-effectiveness ratio proportionally. cOnclusiOns: Despite heterogeneity in methodology across studies, similar trend of cost-effectiveness of competing prevention strategies was witnessed. In light of the trial results of the new nonavalent HPV vaccine, which provides protection against five additional types of the virus, the optimal prevention strategy needs to be reassessed within local context. Objectives: To conduct a pharmacoeconomic evaluation of the application of fulvestrant compared with docetaxel and paclitaxel in the treatment of metastatic breast cancer in second-line chemotherapy. MethOds: Literature review of clinical effectiveness and safety of use of fulvestrant was conducted. Assess of the quality of research and level of evidence obtained in these results was performed. Direct medical costs consisted of the cost of the drug, the cost of patient management and correction of side effects. Duration of therapy, its effectiveness and side effects were obtained from relevant studies on clinical effectiveness (CONFIRM 2013 , S. Jones et al. 2005 . The cost of certain hematologic side effects have been taken from the study Belousov DU et al, 2012 . To estimate the duration of hospital stay in the development of not hematological side effects, conducted a survey of experts. After calculating the total medical costs on compared regimens was conducted cost -effectiveness analysis with the calculation of CER. ResultsAccording to studies CONFIRM, 2013 and S. Jones et al. 2005 ., in patients taking fulvestrant PFS and OS were to 6.5 and 26.4 months, docetaxel -5,7 and 15.4 months, paclitaxel -3,6 and 12.7 months. The total cost of treatment were maximal for the docetaxel -17685 USD, significantly lower for fulvestrant -11803 USD and the minimal for paclitaxel -7205 USD Costeffectiveness analysis showed that in spite of the average cost of treatment, taking into account its effectiveness in PFS and OS, the best CER was shown for fulvestrant, followed by paclitaxel and docetaxel. The sensitivity analysis showed that the simulation results are resistant to increase of the prices for fulvestrant i up to 12%. cOnclusiOns: The use of fulvestrant for the treatment of metastatic breast cancer in second-line chemotherapy is more cost effective than the appointment of docetaxel and paclitaxel.
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